Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing

Marisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi · 2026

Read Development and validation of high-dose methotrexate population pharmacokinetic models to inform clinical decisions on dosing by Marisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197298.txt.

Description

Marisa H Blackman and colleagues built and tested drug-level models for high-dose methotrexate in 2026. Methotrexate treats leukemia, bone cancer, and lymphoma, but slow clearing from the body can cause grave harm. A good model could guide dose choices and blood test timing.

The team built a new model from 208 adults treated at one medical center. Body size, kidney function, and sex shaped clearing in the model. Their model forecast the first blood level, at twenty-four hours, with the best accuracy and precision. Rival models did better at later times in some checks. The authors suggest a staged plan: their model first, then updated forecasts as levels come in.

Catalog record

CREATORMarisa H Blackman, Bradley Yelvington, Cole Beck, Manuel Cortez, Leena Choi
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13197298

Browse the full library · About the Tower of Babel